• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Outside developers suspend Sport medical ‘bot program until Titan Medical can pay its bills

Outside developers suspend Sport medical ‘bot program until Titan Medical can pay its bills

August 16, 2016 By Brad Perriello

Titan MedicalThe product developers Titan Medical (CVE:TMD) hired to help create its Sport robot-assisted surgery platform have suspended development until the company can cover its bills, and $16 million in financing from a Chinese private equity firm might not happen after all, Titan said yesterday.

The Toronto-based company said its product developers “have decided to temporarily suspend development work of the Sport surgical system until such time that the company has sufficient financing to cover current and future work orders projected over a 6-month period.”

“As well, the previously announced $16.0 million equity investment from Shanghai JuGu Equity Investment Fund Co. Ltd. that was expected to close on June 30, 2016, and was subsequently extended to August 15, 2016, has not closed as of the date hereof,” Titan said, noting that there’s no assurance that the financing will close on its previous terms  “if at all.”

“The company’s board of directors is exploring strategies to raise financing necessary to allow the company to resume its development of the Sport surgical system,” Titan said, noting that the suspended development program might mean a delay in filing for 510(k) clearance from the FDA.

“Our immediate focus is securing the financing to resume the development of the Sport surgical system so we can capitalize on what we see as an enormous marketplace opportunity,” CEO John Hargrove said in prepared remarks. “I, along with the board of directors, am aggressively exploring financing strategies to minimize the disruption and continue the progress we achieved over the past few months.”

The pre-revenue-stage company also reported its 2nd-quarter results, paring its losses by -3.8% compared with Q2 2015, to -$7.9 million, or -5¢ per share.

TMD shares, which closed down -2.4% at 64.6¢ (C83¢) apiece yesterday, plunged another -33.7% to 42.7¢ (C55¢) today in early trading.

(C$1 = $0.777391)

Filed Under: Clinical Trials, Funding Roundup, Surgical Robotics, Wall Street Beat Tagged With: Product Development, titanmedical

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy